Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 176 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostatic Neoplasms
Interventions
GM-CSF, Ketoconazole, Mitoxantrone
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
AML
Interventions
Etoposide, Cytarabine, Lenalidomide, Mitoxantrone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm
Interventions
Cladribine, Cytarabine, Granulocyte Colony-Stimulating Factor, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Interventions
cyclosporine, pravastatin sodium, mitoxantrone hydrochloride, etoposide, bone marrow aspiration
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
Dasatinib, Mitoxantrone, Cytarabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Phase 1Phase 2 Interventional Results available

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

NCT02553460
Conditions
Acute Lymphoblastic Leukemia
Interventions
ITMHA, Dexamethasone, Mitoxantrone, Pegaspargase, Asparaginase Erwinia Chrysanthemi, Bortezomib, Vorinostat, Cyclophosphamide, Mercaptopurine, Methotrexate, Leucovorin Calcium, Cytarabine, Etoposide, Vincristine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 365 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 6 more
Conditions
Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Decitabine, Filgrastim, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
Drug · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Prostate Adenocarcinoma
Interventions
Estramustine, Docetaxel, Carboplatin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostate Cancer
Interventions
IMC-A12, Mitoxantrone, Prednisone, IMC-1121B (ramucirumab)
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
La Jolla, California • New Haven, Connecticut • Boca Raton, Florida + 28 more
Conditions
AML
Interventions
Sirolimus, Mitoxantrone, Etoposide, Cytarabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Conditions
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma
Interventions
dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone, allogeneic hematopoietic stem cell transplantation, CliniMACS
Drug · Biological · Other + 2 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
San Diego, California • Memphis, Tennessee • Fort Worth, Texas
Conditions
Cancer, Prostate
Interventions
Mitoxantrone, Siltuximab, Prednisone
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Norwalk, Connecticut • Port Saint Lucie, Florida • Atlanta, Georgia + 8 more
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitts Leukemia/Lymphoma, Chronic Myelogenous Leukemia
Interventions
CLAG-M
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Valhalla, New York
Conditions
Chronic Lymphocytic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab, Filgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia
Interventions
asparaginase, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, mitoxantrone hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
1,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
178
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 141 more
Conditions
Lymphoma, Follicular
Interventions
inotuzumab ozogamicin, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, dexamethasone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
17
States / cities
Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more
Conditions
Prostate Cancer
Interventions
docetaxel, mitoxantrone hydrochloride, conventional surgery
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Portland, Oregon
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cytarabine, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Myeloid Leukemias, AML, Leukemia, CML
Interventions
Rapamycin, Mitoxantrone, Etoposide, Cytarabine, Rapamycin + MEC
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Leukemia, Myelocytic, Acute
Interventions
Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
8
States / cities
Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more
Conditions
Non-Hodgkin's Lymphoma
Interventions
Mitoxantrone Hydrochloride Liposome
Drug
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Canton, Ohio
Conditions
Relapsed Acute Leukemia, Refractory Acute Leukemia, High-Risk Myelodysplasia
Interventions
PD 0332991
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Conditions
Metastatic Prostate Cancer
Interventions
Mitoxantrone, Prednisone, Sorafenib
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
La Verne, California • Atlanta, Georgia • Macon, Georgia + 7 more